TABLE 3.
Descriptive and intra-group comparison of treatment effects.
|
Repeated measures ANOVA |
Post Hoc analysis - Mean within-group differences |
|||||||||||||||
| Outcome | Group |
T0 |
T1 |
T2 |
IC 95% T0-T1 |
IC 95% T0–T2 |
||||||||||
| Mean | SD | Mean | SD | Mean | SD | Time p-value | P-value | Mean diff | LB | UP | P-value | Mean diff | LB | UP | ||
| Perimeter CoP | ||||||||||||||||
| Condition 1 | EG | 179.53 | 81.51 | 157.47 | 52.77 | 159.87 | 66.52 | 0.11 | 0.064 | 22.07 | –1.50 | 45.63 | 0.111 | 19.67 | –5.11 | 44.44 |
| CG | 178.50 | 97.74 | 202.86 | 88.46 | 203.57 | 83.21 | 0.14 | 0.122 | –24.36 | –56.21 | 7.50 | 0.132 | –25.07 | –58.80 | 8.66 | |
| Condition 2 | EG | 245.47 | 110.74 | 272.80 | 122.33 | 215.67 | 84.93 | 0.015∗ | 0.042 | –27.33 | –53.51 | –1.15 | 0.121 | 29.8 | –8.94 | 68.54 |
| CG | 245.93 | 101.21 | 277.36 | 88.57 | 267.00 | 94.14 | 0.29 | 0.182 | –31.43 | –79.63 | 16.77 | 0.399 | –21.07 | –73.24 | 31.09 | |
| Condition 3 | EG | 252.20 | 146.18 | 242.27 | 111.37 | 202.80 | 71.12 | 0.23 | 0.767 | 9.93 | –60.63 | 80.50 | 0.155 | 49.40 | –21.17 | 119.97 |
| CG | 224.29 | 84.04 | 278.14 | 114.42 | 215.57 | 74.55 | 0.06 | 0.098 | –53.86 | –119.02 | 11.31 | 0.619 | 8.71 | –28.26 | 45.69 | |
| Condition 4 | EG | 259.33 | 59.87 | 218.40 | 90.33 | 211.20 | 57.31 | 0.09 | 0.016∗ | 40.93 | 8.73 | 73.13 | 0.019∗ | 48.13 | 9.05 | 87.22 |
| CG | 256.07 | 111.09 | 306.79 | 132.30 | 283.71 | 106.98 | 0.16 | 0.024∗ | –50.71 | –93.66 | –7.77 | 0.242 | –27.64 | –76.41 | 21.12 | |
| Condition 5 | EG | 381.27 | 164.00 | 281.07 | 111.81 | 287.67 | 82.81 | 0.02∗ | 0.024∗ | 100.20 | 14.92 | 185.48 | 0.030 | 93.60 | 10.71 | 176.49 |
| CG | 397.00 | 136.64 | 416.14 | 130.23 | 388.71 | 140.33 | 0.72 | 0.517 | –19.14 | –81.19 | 42.91 | 0.846 | 8.29 | –82.13 | 98.70 | |
| Condition 6 | EG | 393.53 | 169.95 | 306.13 | 125.92 | 273.93 | 86.41 | 0.013∗ | 0.056 | 87.40 | –2.67 | 177.47 | 0.008∗ | 119.60 | 37.04 | 202.16 |
| CG | 393.00 | 184.78 | 404.71 | 144.07 | 362.14 | 160.45 | 0.56 | 0.812 | –11.71 | –115.94 | 92.51 | 0.427 | 30.86 | –50.39 | 112.10 | |
| Area CoP | ||||||||||||||||
| Condition 1 | EG | 74.40 | 45.04 | 69.60 | 51.57 | 59.07 | 41.14 | 0.36 | 0.687 | 4.80 | –20.26 | 29.86 | 0.091 | 15.33 | –2.76 | 33.43 |
| CG | 77.00 | 46.97 | 83.57 | 54.32 | 87.21 | 53.85 | 0.64 | 0.619 | –6.57 | –34.40 | 21.26 | 0.498 | –10.21 | –41.88 | 21.45 | |
| Condition 2 | EG | 152.07 | 127.69 | 186.87 | 144.97 | 121.07 | 103.00 | 0.08 | 0.187 | –34.80 | –88.64 | 19.04 | 0.289 | 31.00 | –29.35 | 91.35 |
| CG | 193.36 | 166.52 | 154.07 | 81.00 | 193.57 | 136.06 | 0.38 | 0.329 | 39.29 | –44.38 | 122.96 | 0.995 | –0.21 | –68.65 | 68.22 | |
| Condition 3 | EG | 142.67 | 126.94 | 164.87 | 128.13 | 115.67 | 69.31 | 0.17 | 0.394 | –22.20 | –76.36 | 31.96 | 0.327 | 27.00 | –30.02 | 84.02 |
| CG | 150.64 | 88.02 | 185.50 | 153.51 | 119.21 | 74.79 | 0.13 | 0.281 | –34.86 | –101.87 | 32.15 | 0.069 | 31.43 | –2.88 | 65.74 | |
| Condition 4 | EG | 129.53 | 60.58 | 86.53 | 60.69 | 85.33 | 24.52 | 0.014∗ | 0.026 | 43.00 | 5.81 | 80.19 | 0.012∗ | 44.20 | 11.02 | 77.38 |
| CG | 139.00 | 107.42 | 153.07 | 125.49 | 152.29 | 119.39 | 0.78 | 0.529 | –14.07 | –61.07 | 32.93 | 0.585 | –13.29 | –64.49 | 37.92 | |
| Condition 5 | EG | 308.73 | 147.56 | 198.47 | 194.77 | 195.60 | 84.82 | 0.05∗ | 0.053 | 110.27 | –1.57 | 222.11 | 0.021∗ | 113.13 | 19.03 | 207.24 |
| CG | 424.36 | 275.20 | 361.00 | 240.39 | 322.36 | 225.86 | 0.35 | 0.399 | 63.36 | –93.67 | 220.39 | 0.183 | 102.00 | –54.52 | 258.52 | |
| Condition 6 | EG | 409.93 | 310.44 | 261.80 | 193.63 | 202.60 | 114.56 | 0.027∗ | 0.096 | 148.13 | –29.90 | 326.17 | 0.012∗ | 207.33 | 51.76 | 362.91 |
| CG | 441.93 | 403.59 | 378.36 | 295.79 | 371.64 | 295.61 | 0.56 | 0.554 | 63.57 | –162.40 | 289.54 | 0.196 | 70.29 | –41.22 | 181.79 | |
EG, experimental group; CG, control group; CoP, center of pression; T0, pre-treatment; T1, post-treatment; T2, 1-month follow-up; 1, open eyes - stable surface condition; 2, closed eyes - stable surface condition; 3, dome - stable surface condition; 4, open eyes - compliant surface condition; 5, closed eyes – compliant surface condition; 6, dome – compliant surface condition; ∗, statistically significant.